Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 7

1.

The complement C5 inhibitor crovalimab in paroxysmal nocturnal hemoglobinuria.

Röth A, Nishimura JI, Nagy Z, Gaàl-Weisinger J, Panse J, Yoon SS, Egyed M, Ichikawa S, Ito Y, Kim JS, Ninomiya H, Schrezenmeier H, Sica S, Usuki K, Sicre de Fontbrune F, Soret J, Sostelly A, Higginson J, Dieckmann A, Gentile B, Anzures-Cabrera J, Shinomiya K, Jordan G, Biedzka-Sarek M, Klughammer B, Jahreis A, Bucher C, Peffault de Latour R.

Blood. 2020 Mar 19;135(12):912-920. doi: 10.1182/blood.2019003399.

2.

Tumor Size and Overall Survival in Patients With Platinum-Resistant Ovarian Cancer Treated With Chemotherapy and Bevacizumab.

Sostelly A, Mercier F.

Clin Med Insights Oncol. 2019 May 28;13:1179554919852071. doi: 10.1177/1179554919852071. eCollection 2019.

3.

Population Pharmacokinetic/Pharmacodynamic Modeling of Tumor Size Dynamics in Pembrolizumab-Treated Advanced Melanoma.

Chatterjee MS, Elassaiss-Schaap J, Lindauer A, Turner DC, Sostelly A, Freshwater T, Mayawala K, Ahamadi M, Stone JA, de Greef R, Kondic AG, de Alwis DP.

CPT Pharmacometrics Syst Pharmacol. 2017 Jan;6(1):29-39. doi: 10.1002/psp4.12140. Epub 2016 Nov 29.

4.

Tumor Static Concentration Curves in Combination Therapy.

Cardilin T, Almquist J, Jirstrand M, Sostelly A, Amendt C, El Bawab S, Gabrielsson J.

AAPS J. 2017 Mar;19(2):456-467. doi: 10.1208/s12248-016-9991-1. Epub 2016 Sep 28. Erratum in: AAPS J. 2017 Mar;19(2):596.

PMID:
27681102
5.

Can we predict chemo-induced hematotoxicity in elderly patients treated with pegylated liposomal doxorubicin? Results of a population-based model derived from the DOGMES phase II trial of the GINECO.

Sostelly A, Henin E, Chauvenet L, Hardy-Bessard AC, Jestin-Le Tallec V, Kirsher S, Leyronnas C, Ligeza-Poisson C, Ramdane S, Salavt J, Van-Hult S, Vannetzel JM, Freyer G, Tod M, Falandry C.

J Geriatr Oncol. 2013 Jan;4(1):48-57. doi: 10.1016/j.jgo.2012.06.004. Epub 2012 Aug 3.

PMID:
24071492
6.

Quantitative evaluation of the combination between cytotoxic drug and efflux transporter inhibitors based on a tumour growth inhibition model.

Sostelly A, Payen L, Guitton J, Di Pietro A, Falson P, Honorat M, Boumendjel A, Gèze A, Freyer G, Tod M.

Fundam Clin Pharmacol. 2014 Apr;28(2):161-9. doi: 10.1111/fcp.12005. Epub 2013 Feb 6.

PMID:
23384250
7.

A template model for studying anticancer drug efflux transporter inhibitors in vitro.

Sostelly A, Payen L, Guitton J, Di Pietro A, Falson P, Honorat M, Valdameri G, Geze A, Boumendjel A, Freyer G, Tod M.

Fundam Clin Pharmacol. 2013 Oct;27(5):544-56. doi: 10.1111/j.1472-8206.2012.01054.x. Epub 2012 Aug 8.

PMID:
22882086

Supplemental Content

Loading ...
Support Center